Evidence map›Paper›PMID 39999809›Full record

ArticleDementia and geriatric cognitive disorders2025

Deciphering Perspectives: A European Survey on Clinical Decision Support Tools for Dementia and Alzheimer's Disease.

Ini Umoh, Xin Xia, Bengt Winblad, Sandar Aye, Emil Aho, Hanneke F M Rhodius-Meester, Linus Jönsson

Abstract read
In one paragraph

Article in Dementia and geriatric cognitive disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ini UmohDepartment of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden.
Xin XiaDepartment of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden.
Bengt WinbladDivision of Neurogeriatrics, Department of NVS, Karolinska Institutet, Solna, Sweden.
Sandar AyeDepartment of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden.
Emil AhoDepartment of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden.
Hanneke F M Rhodius-MeesterAlzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, De Boelelaan, Amsterdam, The Netherlands.
Linus JönssonDepartment of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTechnological advancements like digital monitoring tools, disease-modifying therapies, and artificial intelligence have been shown to improve the clinical management of neurocognitive diseases like Alzheimer's disease (AD). To enhance implementation in daily practice, users' input is essential in the technology development process. This study aimed to determine clinician's perspective of clinical decision support systems (CDSS) in the management of dementia and AD.

methodA survey was conducted targeting clinicians practicing in the field of dementia across Europe. A sixty-five-item digital questionnaire was administered, and opinions were inquired across the domains of diagnosis, disease-modifying therapy, and prognosis, including factors that affect tool implementation and utilization.

resultsEighty-four clinicians (including specialist physicians, psychologists, and nurses) responded to this survey, and more than 50% had no knowledge or experience with CDSS. Most of the respondents reported the ability to predict the likelihood of AD as the most important diagnostic function. It was surprising to find the middling responses for the ability to predict amyloid positivity. The majority indicated assessment of treatment eligibility for disease-modifying therapy as vital, and the ability to predict cognitive and functional decline as the most important prognostic functions. Data accuracy and ease of use were noted as most necessary to facilitate CDSS adoption and implementation.

conclusionFindings from this study contribute to the future development of CDSS in this field, especially regarding the approval and imminent use of disease-modifying therapies, a comprehensive tool that is precise and user friendly would improve clinical decisions and efficiency.

Indexed as

Alzheimer DiseaseAttitude of Health PersonnelDecision Support Systems, ClinicalDementiaEuropeFemaleHumansMalePrognosisSurveys and QuestionnairesAlzheimer’s diseaseClinical decision support systemClinician perspectiveDementia

Identifiers

PMID39999809
PMCPMC12500249

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.